Our Future Health is an ambitious collaboration between the public, charity and private sectors. We are a charity and we have initial funding from UK Research and Innovation (UKRI) – the UK Government-funded body that invests in science and research – to develop our programme. Support will also come from charities and companies that make medicines, equipment used in healthcare and related technologies.
Dr Andrew Roddam
Andrew is an internationally renowned epidemiologist. He started his career at University of Oxford after studying there for a DPhil (Statistics) and has held a wide range of roles across both academia and industry applying epidemiological methods to advance the understanding of human disease. Andrew was most recently Vice President Data Strategy at GSK before joining as our CEO in April 2020.
Chief Communications Officer
Michael joined Our Future Health in May 2020 and looks after our communications, policy and public affairs. He previously spent a year at the UK BioIndustry Association, following a 17-year career as a Senior Civil Servant responsible for communications teams at Innovate UK, the Department of Work and Pensions, the Home Office and the Prime Minister’s Office at No10 Downing Street. He studied psychology at the University of Durham.
Dr Saskia Sanderson
Chief Behavioural Scientist
Saskia has over 20 years’ experience as an academic researcher conducting research in the field of psychology applied to genomics, including academic research appointments at University College London (UCL), the National Institutes of Health in Bethesda, US and at the Icahn School of Medicine at Mount Sinai, New York, US. Saskia holds a PhD in health psychology applied to genomics from UCL.
Dr Fiona Reddington
Executive Director of Strategic Partnerships
Fiona helped to establish Our Future Health in 2019 as our Interim Chief Operating Officer before taking responsibility for building our partnerships across the NHS, charities, and industry. She previously spent over ten years at Cancer Research UK where she was responsible for research portfolios in clinical trials, population research, prevention and early diagnosis. She holds a PhD (Neurophysiology) from Kings College London (UMDS).
Chief Operating Officer
Jo is a senior digital leader, COO, and start-up founder with broad experience in delivering digital platforms, products, and software services. She has successfully led operations and digital delivery in large corporate, start-up, public and charitable sectors over a career spanning more than two decades.
Director of Policy and Public Affairs
Louisa leads work across a wide range of strategic issues and engage effectively with our stakeholders in government, industry, and the research community to influence and promote our interests. She joined Our Future Health in January 2021 on a 12-month secondment from the civil service where, most recently, she was part of the Vaccines Taskforce, helping to secure coronavirus vaccines for the UK.
Chief Technology Officer
Marko’s role is to help create a secure and scalable set of platforms for Our Future Health and create a high-quality data resource available for researchers. He has over 25 years’ experience leading technology teams and developing innovations in academia, corporations, and start-ups, in both the UK and US. He is also a Non-Executive Director on the Board of NHS Digital. He studied Computer Science at Cambridge University, and has a PhD in Computer Science (Artificial Intelligence) from Stanford.
Professor David Hunter MBBS MPH ScD FRACPHM
Chief Science Adviser
David combines his work as our science adviser with his role as Richard Doll Professor of Epidemiology and Medicine and Director of the Translational Epidemiology Unit at the Nuffield Department of Population Health, University of Oxford.
Professor John Deanfield CBE BA Hons (Cantab), MB, BChir, FRCP, FESC, FACC
Chief Medical Adviser
John Deanfield is Professor of Cardiology at University College London (UCL) and the Director of National Institute for Cardiovascular (CV) Outcomes Research (NICOR). He currently Chairs the UK’s National Health Check Programme Review. He has been at the forefront of efforts to prevent heart disease and stroke from early intervention, which he has termed as “investing in your arteries”.
Dr Michael B Cook
Executive Director of Epidemiology
Michael is a senior epidemiologist with broad and contemporary expertise in research, program management, and scientific leadership. Michael was previously a tenured, Senior Investigator at the US National Institutes of Health. He has designed and conducted numerous studies to advance etiologic understanding, clinical management, and prevention of chronic disease.
If you would like to contact the Our Future Health team please email us at [email protected]
To contact our communications team for media and press enquiries please email [email protected]
Our Future Health is a charity registered with the Charity Commission for England and Wales (charity number 1189681) and is a private company limited by guarantee (company number 12212468).
Our governance is designed to ensure legal compliance, the privacy of our participants and the security of their data. It also ensures we can work effectively with the partners who help to fund, support and deliver our programme.
Our Future Health is governed by a Board of Trustees, who are ultimately responsible for the policies, activities and assets of Our Future Health and provide strategic leadership. Trustees serve on the Board in a voluntary capacity and do not receive remumeration. The Trustees of Our Future Health are:
- Dr Timothy Peakman OBE
- Dr Sir Harpal Kumar
- Professor Sir John Bell FRS HonFREng PMedSci
- Professor Fiona Watt FRS FMedSci (MRC Trustee)
Our Future Health governance includes a range of Advisory Boards and an Access and Review Committee that all help guide and shape our programme:
- The Access Review Committee is responsible for access to Our Future Health data, samples and participants and will report to the main Board
- The Ethics Advisory Board monitors the development of Our Future Health to make sure it meets high ethical and governance standards across all its activities
- The Diversity & Inclusion Advisory Board supports us in our aim to recruit participants from a diverse range of backgrounds
- The Founders Advisory Board brings together the charity & industry partners who are co-funding the establishment of the Our Future Health programme
- The Public & Participant Advisory Board comprises members of the general public and study participants to work with us on all aspects of Our Future Health
- The Scientific Advisory Board is responsible for making sure that all Our Future Health research meets the highest ethical and scientific standards
- The Technology Advisory Board has oversight of main Our Future Health platform technology solutions and decisions
- The Implementation Advisory Board oversees decisions which will impact the delivery and implementation of the Our Future Health programme
Our Future Health is an ambitious collaboration between the public sector, charities and companies that make medicines, equipment used in healthcare and related technologies.
Our programme has initial funding of £79 million from UK Research and Innovation – the UK Government-funded body that invests in science and research. This funding is being used to set up and begin to deliver the programme.
We are aiming to raise additional resources of around £160 million from charities and companies that do medical research and make the medicines, treatments, tests and equipment used to help treat, detect and diagnose diseases.
Our aims and values
The overarching aim of Our Future Health is to help people live healthier lives for longer through better prevention, earlier detection and improved treatment of diseases. We aim to speed up the discovery of new methods of early disease detection, and the evaluation of new diagnostic tools, to help identify and treat diseases early when outcomes are usually better.
Our ambition is to recruit up to 5 million adults from across the UK to create a diverse and inclusive cohort of people who have consented to participate in the research.
The specific aims of our programme are:
- To build a resource linking multiple sources of health and health-relevant information, including genetic data, on millions of people in the UK, to facilitate basic discovery research by academic and commercial researchers on early indicators of disease
- To analyse the data in the resource to estimate personal disease risk information for participants, based on genetic and non-genetic information, and offer this estimated personal health information to participants who wish to receive it
- To re-contact sub-groups of participants generally for additional samples, non-routine data and secondary studies over time
- To re-contact participants on a risk-stratified basis (i.e. recall-by-genotype/phenotype or sociodemographic characteristics) over time specifically to enable secondary studies by academic and commercial researchers that is greatly enhanced by being able to identify highly enriched sub-populations/sub-cohorts of participants
Our values guide how we behave in all our work, our engagement with others and in our communications:
- We must always be honest and transparent in our intentions and with the people and partners who contribute to this programme. The full benefits of this research can only be realised at scale and over time – it is essential that we build and retain the trust of all involved, by treating and protecting their contributions with the care we would expect.
- We can only achieve our goal by creating new partnerships and ways of working, bringing together people and organisations that can contribute and empowering, encouraging and supporting them to do so.
- We are ambitious and committed to reducing the impact of diseases for everyone. Our goal is to fundamentally change the way researchers detect, treat and prevent diseases. This requires us to be challenging and bold when necessary, but only in support of that goal and for the benefit of participants.
- For everyone to be able to benefit from this research programme, it is critical that it represents all kinds of people. We aim to make potentially complex subjects and processes as accessible as possible, without compromising the results.